leadf
logo-loader
viewImmutep Ltd
(
ASX:IMM
)

Immutep with Proactive at the ASX Small and Mid Cap Conference

Immutep Ltd (ASX:IMM)'s Marc Voigt speaks with Proactive at the ASX Small and Mid Cap Conference - September 2021. The company's focused on the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Its current lead product candidate is eftilagimod alpha, a soluble LAG-3 fusion protein (LAG-3Ig).

Quick facts: Immutep Ltd

Follow
ASX:IMM

Price: 0.565 AUD

Market Cap: $422.71 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Base Resources highlights enhanced DFS for Toliara project in Madagascar

Base Resources Ltd's Kevin Balloch talks Proactive through an enhanced definitive feasibility study on its Toliara project in Madagascar. It's revealed a post-tax/pre-debt net present value of US$1bn and a 3.5 average revenue to cost of sales ratio over an initial 38-year mine life. Life-of-mine...

1 hour, 44 minutes ago

2 min read